The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Blueprint Genetics; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Ipsen; Lilly; Merck; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pfizer; PharmaMar; Roche; Sanofi; SERVIER
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb Foundation; Pfizer
Speakers' Bureau - AstraZeneca Spain; Roche
Expert Testimony - Medsir; Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Santiago Ponce Aix
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche
Travel, Accommodations, Expenses - AstraZeneca; Merck; Roche
 
Isidoro C. Barneto - Aranda
No Relationships to Disclose
 
Egbert F. Smit
Honoraria - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Merck KGaA; Merck KGaA
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Jose Antonio Lopez-Vilariño
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Antonio Nieto
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Carmen Maria Kahatt
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
 
Ali Hassan Zeaiter
Employment - PharmaMar
Leadership - PharmaMar
Stock and Other Ownership Interests - PharmaMar; SERVIER
Honoraria - PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Sophie Cousin
No Relationships to Disclose
 
Helge Bischoff
No Relationships to Disclose
 
Jaromir Roubec
No Relationships to Disclose
 
Konstantinos Syrigos
Consulting or Advisory Role - Amgen (Inst); Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Roche
 
Luis Paz-Ares
No Relationships to Disclose